Flucytosine-13C,15N2
Based on 1 Customer Validation
Flucytosine-13C,15N2 (NSC 103805-13C,15N2; Ro 2-9915-13C,15N2) is a 13C- and 15N-labeled Flucytosine (HY-B0139).
For research use only. We do not sell to patients.
- CAS No.: 1216616-31-7
- Formula: C313CH4FN15N2O
- Molecular Weight:132.07
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1216616-31-7
-
Unlabeled Cas 2022-85-7
-
Appearance Solid
-
Molecular Weight 132.07
-
Formula C313CH4FN15N2O
-
Color White to off-white
-
SMILES
NC1=C(C=[15N][13C]([15NH]1)=O)F
-
Synonyms
5-Fluorocytosine-13C,15N2; NSC 103805-13C,15N2; Ro 2-9915-13C,15N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-246. [Content Brief]
[2]. Vermes A, et al. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000 Aug;46(2):171-9. [Content Brief]
[3]. Te Dorsthorst DT, et al. In vitro interaction of flucytosine combined with amphotericin B or fluconazole against thirty-five yeast isolates determined by both the fractional inhibitory concentration index and the response surface approach. Antimicrob Agents Chemother. 2002 Sep;46(9):2982-9. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Flucytosine-13C,15N2 Related Classifications
HY-B0139S Related Classifications
Powered by Bioz